Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Testosterone
Drug ID BADD_D02170
Description Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]
Indications and Usage To be used as hormone replacement or substitution of diminished or absent endogenous testosterone. Use in males: For management of congenital or acquired hypogonadism, hypogonadism associated with HIV infection, and male climacteric (andopause). Use in females: For palliative treatment of androgen-responsive, advanced, inoperable, metastatis (skeletal) carcinoma of the breast in women who are 1-5 years postmenopausal; testosterone esters may be used in combination with estrogens in the management of moderate to severe vasomotor symptoms associated with menopause in women who do not respond to adequately to estrogen therapy alone.
Marketing Status Prescription; Discontinued
ATC Code G03BA03
DrugBank ID DB00624
KEGG ID D00075
MeSH ID D013739
PubChem ID 6013
TTD Drug ID D06XMU
NDC Product Code 48087-0113; 69238-1013; 49452-7652; 66887-004; 63629-2125; 0591-2114; 63629-2124; 0832-1120; 65089-0050; 63629-8455; 16714-967; 0603-7831; 0591-2363; 42667-5511; 49884-418; 82393-113; 24979-078; 76420-684; 43598-304; 38779-2598; 66887-001; 44132-008; 0832-1121; 64025-0010; 22552-0009; 0023-5990; 0051-8462; 38779-0163; 60870-0251; 45802-754; 70492-002; 51927-1026; 0591-2924; 71589-013; 0591-2921; 0591-2926; 51552-0029; 62332-488; 16714-968; 0245-0872; 44132-006; 0245-0871; 45802-366; 49452-7657; 0591-2925; 0051-8425; 76420-687; 68382-362; 76420-686; 0591-3216; 60592-721; 24979-130; 12875-8248; 45802-610; 76003-1083; 38779-2936; 0009-0074; 49884-510; 68180-943; 43647-568; 0051-8450; 0802-8068; 71589-011; 62991-2150; 69097-363; 0023-5992; 0009-5020; 0591-3524; 69339-158; 43742-1242; 76420-685; 70700-112; 68180-941; 63481-183; 43742-1436; 43742-0677; 63629-2352; 76420-699; 51552-0564; 16714-969; 0591-3217; 45802-281; 62332-552
Synonyms Testosterone | 17-beta-Hydroxy-4-Androsten-3-one | 17 beta Hydroxy 4 Androsten 3 one | Androtop | Histerone | Sterotate | Sustanon | Androderm | Testoderm | Testolin | Testopel | Testosterone Sulfate | AndroGel | 8-Isotestosterone | 8 Isotestosterone | 17-beta-Hydroxy-8 alpha-4-Androsten-3-one | 17 beta Hydroxy 8 alpha 4 Androsten 3 one | Andropatch | Testim
Chemical Information
Molecular Formula C19H28O2
CAS Registry Number 58-22-0
SMILES CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Depression suicidal19.15.01.004--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis acneiform23.02.01.004--
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis contact12.03.01.040; 10.01.01.003; 23.03.04.004--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.004--Not Available
Diarrhoea07.02.01.001--
Dilatation ventricular02.04.02.0260.000891%Not Available
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Dissociation19.14.01.002--Not Available
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug abuse19.07.02.010--Not Available
Drug dependence19.07.02.009--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea exertional02.01.03.003; 22.02.01.005--Not Available
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Eczema23.03.04.006--
Ejaculation disorder21.03.01.002--
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 26 Pages